J 2015

Analysis of Prognostic Significance of Merkel Cell Polyomavirus in Chronic Lymphocytic Leukemia

TRIZULJAK, Jakub, Josef SROVNAL, Karla PLEVOVÁ, Yvona BRYCHTOVÁ, Lukáš SEMERÁD et. al.

Basic information

Original name

Analysis of Prognostic Significance of Merkel Cell Polyomavirus in Chronic Lymphocytic Leukemia

Authors

TRIZULJAK, Jakub (703 Slovakia, guarantor, belonging to the institution), Josef SROVNAL (203 Czech Republic), Karla PLEVOVÁ (203 Czech Republic, belonging to the institution), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Lukáš SEMERÁD (203 Czech Republic, belonging to the institution), Denisa BAKEŠOVÁ (703 Slovakia, belonging to the institution), Eva LÉTALOVÁ (203 Czech Republic, belonging to the institution), Andrea BENEDÍKOVÁ (203 Czech Republic), Jiří MAYER (203 Czech Republic, belonging to the institution), Marian HAJDÚCH (203 Czech Republic), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution) and Michael DOUBEK (203 Czech Republic, belonging to the institution)

Edition

Clinical Lymphoma Myeloma & Leukemia, Dallas, Cig Media Group, 2015, 2152-2650

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.316

RIV identification code

RIV/00216224:14110/15:00083517

Organization unit

Faculty of Medicine

UT WoS

000357967700010

Keywords in English

Chronic lymphocytic leukemia; Merkel cell polyomavirus; Overall survival; Polymerase chain reaction; Prognostic factors

Tags

International impact, Reviewed
Změněno: 28/4/2016 13:51, Ing. Mgr. Věra Pospíšilíková

Abstract

V originále

Merkel cell polyomavirus (MCPyV) has been found to be associated with chronic lymphocytic leukemia (CLL). We evaluated its prognostic significance in CLL. MCPyV occurrence seems to be a relatively rare event during the course of CLL. MCPyV is also unlikely to influence the outcome of CLL patients. Background: Merkel cell polyomavirus (MCPyV), a ubiquitous DNA tumor virus, has been found to be associated with Merkel cell carcinoma and chronic lymphocytic leukemia (CLL). Previous studies have reported conflicting results on the frequency and potential pathogenetic role of MCPyV in CLL. The aim of this study was to evaluate MCPyV's association with CLL and its prognostic significance. Patients and Methods: Between 2006 and 2013, DNA samples obtained from CLL patients (n = 119) before treatment were tested for MCPyV using quantitative real-time polymerase chain reaction analysis and verified by gel electrophoresis. Only samples testing positive by both methods were considered valid. Results: We found that 13 (11%) of 119 CLL cases were positive for MCPyV. Between the groups of MCPyV-positive and -negative patients, there was no significant difference in the sex, age, cytogenetics, presence of p53 defect, or immunoglobulin heavy chain (IGHV) mutational status. In the subset of MCPyV-negative patients, advanced Rai stage (III to IV) was found more frequently, and therapy was initiated more often. There was no difference in overall response rate, median progression-free survival, and overall survival between both groups. We did not observe any new positivity after treatment in initially MCPyV-negative patients. Conclusion: This study provides the first analysis of the prognostic role of MCPyV in CLL. MCPyV occurrence seems to be a relatively rare event during the course of CLL. MCPyV is also unlikely to influence the outcome of CLL patients.

Links

ED1.1.00/02.0068, research and development project
Name: CEITEC - central european institute of technology
EE2.3.20.0045, research and development project
Name: Podpora profesního růstu a mezinárodní integrace výzkumných týmů v oblasti molekulární medicíny
NT13493, research and development project
Name: Molekulární charakterizace B buněčných receptorů a jejich vztah k evoluci genetických změn u chronické lymfocytární leukémie
7E13008, research and development project
Name: Next Generation Sequencing Platform for Targeted Personalized Therapy of Leukemia (Acronym: NGS-PTL)
Investor: Ministry of Education, Youth and Sports of the CR